Principal Megan Chacon on the Future of Biopharma Patents Under Second Term of the Trump Administration

Principal Megan Chacon shares insights on the potential impact of President-elect Donald Trump's second term on the life sciences industry and IP policies. In remarks to Life Sciences Intellectual Property Review, Chacon discusses the potential differences between the Biden and Trump administration, zeroing in on march-in-rights and the Inflation Reduction Act (IRA).

Excerpt: "Megan Chacon, principal at Fish & Richardson, notes that while Trump's selection of Kennedy as an adviser on health policy has 'raised eyebrows' at the FDA, a second Trump administration likely will offer 'a reprieve to biopharma companies on the patent side.'" 

Read the full article: Trump’s return sparks calls for pro-patent agenda